These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23369463)

  • 1. T-cadherin loss promotes experimental metastasis of squamous cell carcinoma.
    Philippova M; Pfaff D; Kyriakakis E; Buechner SA; Iezzi G; Spagnoli GC; Schoenenberger AW; Erne P; Resink TJ
    Eur J Cancer; 2013 May; 49(8):2048-58. PubMed ID: 23369463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cadherin enhances cell-matrix adhesiveness by regulating beta1 integrin trafficking in cutaneous squamous carcinoma cells.
    Mukoyama Y; Utani A; Matsui S; Zhou S; Miyachi Y; Matsuyoshi N
    Genes Cells; 2007 Jun; 12(6):787-96. PubMed ID: 17573778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand activation of overexpressed epidermal growth factor receptor results in colony dissociation and disturbed E-cadherin function in HSC-1 human cutaneous squamous carcinoma cells.
    Fujii K; Furukawa F; Matsuyoshi N
    Exp Cell Res; 1996 Feb; 223(1):50-62. PubMed ID: 8635495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cadherin loss induces an invasive phenotype in human keratinocytes and squamous cell carcinoma (SCC) cells in vitro and is associated with malignant transformation of cutaneous SCC in vivo.
    Pfaff D; Philippova M; Buechner SA; Maslova K; Mathys T; Erne P; Resink TJ
    Br J Dermatol; 2010 Aug; 163(2):353-63. PubMed ID: 20394625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion.
    Klucky B; Mueller R; Vogt I; Teurich S; Hartenstein B; Breuhahn K; Flechtenmacher C; Angel P; Hess J
    Cancer Res; 2007 Sep; 67(17):8198-206. PubMed ID: 17804733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-Cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma: impact on cell motility.
    Kyriakakis E; Maslova K; Philippova M; Pfaff D; Joshi MB; Buechner SA; Erne P; Resink TJ
    J Invest Dermatol; 2012 Sep; 132(9):2275-85. PubMed ID: 22592160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts.
    Kyriakakis E; Maslova K; Frachet A; Ferri N; Contini A; Pfaff D; Erne P; Resink TJ; Philippova M
    Cell Signal; 2013 May; 25(5):1044-53. PubMed ID: 23411345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E-cadherin suppression accelerates squamous cell carcinoma progression in three-dimensional, human tissue constructs.
    Margulis A; Zhang W; Alt-Holland A; Crawford HC; Fusenig NE; Garlick JA
    Cancer Res; 2005 Mar; 65(5):1783-91. PubMed ID: 15753375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential down-regulation of E-cadherin with squamous cell carcinoma progression: loss of E-cadherin via a prostaglandin E2-EP2 dependent posttranslational mechanism.
    Brouxhon S; Kyrkanides S; O'Banion MK; Johnson R; Pearce DA; Centola GM; Miller JN; McGrath KH; Erdle B; Scott G; Schneider S; VanBuskirk J; Pentland AP
    Cancer Res; 2007 Aug; 67(16):7654-64. PubMed ID: 17699770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical effects of T-cadherin on squamous cell carcinoma: up- and down-regulation increase xenograft growth by distinct mechanisms.
    Pfaff D; Philippova M; Kyriakakis E; Maslova K; Rupp K; Buechner SA; Iezzi G; Spagnoli GC; Erne P; Resink TJ
    J Pathol; 2011 Dec; 225(4):512-24. PubMed ID: 21766307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck.
    Sauter ER; Nesbit M; Watson JC; Klein-Szanto A; Litwin S; Herlyn M
    Clin Cancer Res; 1999 Apr; 5(4):775-82. PubMed ID: 10213212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
    Amin DN; Bielenberg DR; Lifshits E; Heymach JV; Klagsbrun M
    Microvasc Res; 2008 May; 76(1):15-22. PubMed ID: 18440031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct P-cadherin expression in cultured normal human keratinocytes and squamous cell carcinoma cell lines.
    Wakita H; Shirahama S; Furukawa F
    Microsc Res Tech; 1998 Nov; 43(3):218-23. PubMed ID: 9840799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
    Sini P; Wyder L; Schnell C; O'Reilly T; Littlewood A; Brandt R; Hynes NE; Wood J
    Clin Cancer Res; 2005 Jun; 11(12):4521-32. PubMed ID: 15958638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of E-cadherin function drives the early stages of Ras-induced squamous cell carcinoma through upregulation of FAK and Src.
    Alt-Holland A; Sowalsky AG; Szwec-Levin Y; Shamis Y; Hatch H; Feig LA; Garlick JA
    J Invest Dermatol; 2011 Nov; 131(11):2306-15. PubMed ID: 21716326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
    Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS
    Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of E-cadherin in mouse skin carcinoma cells enhances a migratory and invasive phenotype linked to matrix metalloproteinase-9 gelatinase expression.
    Llorens A; Rodrigo I; López-Barcons L; Gonzalez-Garrigues M; Lozano E; Vinyals A; Quintanilla M; Cano A; Fabra A
    Lab Invest; 1998 Sep; 78(9):1131-42. PubMed ID: 9759657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
    Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coxsackie and adenovirus receptor is a critical regulator for the survival and growth of oral squamous carcinoma cells.
    Saito K; Sakaguchi M; Iioka H; Matsui M; Nakanishi H; Huh NH; Kondo E
    Oncogene; 2014 Mar; 33(10):1274-86. PubMed ID: 23503462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.